Paraneoplastic Syndromes - 51 Studies Found
Completed |
: A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) : Lambert Eaton Myasthenic Syndrome : 2011-06-17 :
|
No longer available |
: Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome : Lambert-Eaton Myasthenic Syndrome : 2011-06-13 : Drug: 3,4 DAP Recommended maximum dosage: 20mg four times daily and if needed an additional 20 mg per da |
Completed |
: MC-5A for Chemotherapy Induced Peripheral Neuropathy : Neuropathy, Paraneoplastic : 2010-12-09 :
|
Completed |
: Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes : Congenital Myasthenic Syndrome : 2010-09-15 : Drug: Albuterol 4 mg twice daily by mouth for adults. The dose for children 6 to 12 years is 2 mg two or |
Available |
: Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine : Lambert-Eaton Myasthenic Syndrome : 2009-10-08 : Drug: 3,4 diaminopyridine 3,4 diaminopyridine up to 80 mg daily in divided doses |
Recruiting |
: The Study of Immune Cell (T Cell) Activity in Patients With Paraneoplastic Neurologic Syndromes : Paraneoplastic Syndromes : 2006-05-17 |
Active, not recruiting |
: Multicenter and Prospective Clinical Registry Study of Anti-N-methyl-D-aspartate Receptor Encephalitis in China : Anti-NMDA Receptor Enphalitis : 2015-09-23 |
Active, not recruiting |
: Ephedrine for the Treatment of Congenital Myasthenia : Myasthenic Syndromes, Congenital : 2007-10-07 : Drug: Ephedrine |
Available |
: Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia and Lambert-Eaton Syndrome :
: 2017-02-21 : Drug: 3,4-Diaminopyridine The investigator will prescribe an initial dose of 3,4 diaminopyridine (DAP) b |
Recruiting |
: Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) : Lambert-Eaton Myasthenic Syndrome : 2016-11-16 :
|